Stock Ratings / Health Care / CVKD / options

EOCN (47) SXTP (50) GRI (38) ERNA (46) ⌘ Pro Terminal →

Cadrenal Therapeutics Inc. (CVKD) Options Positioning, Max Pain & Unusual Sweeps

$0.94 -0.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.94

Cadrenal Therapeutics Inc. (CVKD) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.94 (-0.27%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CVKD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY CVKD SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.91+19.8% Next Q

Q2 (-2Q)

Grade E$1.09-11.9% Next Q

Q3 (-1Q)

Grade E$0.96-2.1% Next Q

Current

Grade D-$0.94-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CVKD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CVKD currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.14) and Max Pain ($0.99) forces dealer call-delta covering toward $14.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CVKD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CVKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CVKD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CVKD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CVKD)

✓Walkthrough of CVKD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CVKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -85.91%▲ RESISTANCE BREAKOUT

2026-10-30O $0.94H $1.00L $0.94C $0.94VOL 80.7K

RES: $0.92SUP: $0.14SMA50: $1.14SMA200: $3.94

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CVKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CVKD Butterfly Map → + Track CVKD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CVKD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CVKD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CVKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CVKD)

Health Care Rank #658 of 1016 ⚔️ EOCN vs CVKD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CVKD vs. EOCN, SXTP, GRI, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cadrenal Therapeutics Inc. (CVKD) ranks #658 by composite RQD confidence (40/100, grade D-) and #974 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, CVKD leads on earnings valuation at N/A trailing P/E, while CVKD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with CVKD at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CVKD ACTIVE Cadrenal Therapeutics Inc.	D-	40/100	—	—	-35.0%	-0.47%	$3.4M	Benchmark Subject
EOCN Eocene Ltd.	D	47/100	—	—	-35.0%	+0.62%	$3.4M	/eocn-vs-cvkd →
SXTP 60 Degrees Pharmaceuticals Inc.	D	50/100	—	22.3%	-35.0%	+11.87%	$3.3M	/sxtp-vs-cvkd →
GRI GRI Bio Inc.	D-	38/100	—	—	-35.0%	-3.38%	$3.4M	/gri-vs-cvkd →
ERNA Ernexa Therapeutics Inc.	D	46/100	—	—	-35.0%	+6.57%	$3.4M	/erna-vs-cvkd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001937993

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cadrenal Therapeutics Inc. (CVKD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.2M, operating cash flow of -$12.6M, and free cash flow of -$12.6M (-71.2% YoY). On the balance sheet, CVKD closed FY2025 with $4.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$13.2M	-$12.6M	-$12.6M	$4.3M	—
FY2024 (FY)	2024-12-31	$0	-$10.7M	-$7.4M	-$7.4M	$10.1M	—
FY2023 (FY)	2023-12-31	$0	-$8.4M	-$3.5M	-$3.5M	—	—

3. CVKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CVKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cadrenal Therapeutics Inc. (NASDAQ: CVKD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.94 (-0.47% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CVKD ranks #658 in composite RQD confidence.

How does CVKD compare to EOCN and SXTP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CVKD carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and SXTP (60 Degrees Pharmaceuticals Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, CVKD leads on earnings multiple (N/A) while CVKD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CVKD?

Per CVKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001937993), Cadrenal Therapeutics Inc. generated $0 in revenue, -$13.2M in net income, and -$12.6M in free cash flow against $4.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CVKD trading relative to its 50-day, 200-day, and 52-week technical levels?

CVKD last traded at $0.94 (-0.47% on volume of 44,042 shares), positioning the stock -17.54% below its 50-day simple moving average ($1.14) and -76.14% below its 200-day simple moving average ($3.94). Across its 52-week range of $0.82 to $13.63, CVKD sits at the 0.9% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.06).

CVKD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CVKD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CVKD.

Direct Sub-Reports: CVKD RQD Cockpit CVKD 12M Forecast CVKD Earnings & Move CVKD Dividends & DRIP CVKD Insiders & 13F CVKD Whale Options CVKD Profit Sankey CVKD News & Why